As a direct therapeutic consequence of these risk estimations ACE-inhibitors, betablockers and statins should be considered in these patients in a case of repeated therapies with different cancer treatments and more importantly interdisciplinary discussion before initiation of cancer treatment is indicated [9, 20–22]. Here, ACE is linked to cancer.